Latigo Biotherapeutics (LTGO) director reports zero shares
Rhea-AI Filing Summary
Latigo Biotherapeutics, Inc. (LTGO) had an initial Form 3 beneficial ownership report filed by Kevin Raidy, who is identified as a director of the company. The filing lists no reportable transactions or holdings, indicating that no equity positions are being reported at this time.
Positive
- None.
Negative
- None.
Key Figures
Buy transactions: 0
Sell transactions: 0
Net buy/sell shares: 0
+2 more
5 metrics
Buy transactions
0
Number of buy transactions reported for Kevin Raidy on this Form 3
Sell transactions
0
Number of sell transactions reported for Kevin Raidy on this Form 3
Net buy/sell shares
0
Net buy or sell share count reported in the transaction summary
Holding entries
0
Number of non-derivative or derivative holding entries reported
Derivative transactions
0
Total derivative transaction count in the transaction summary
Key Terms
Form 3, beneficial ownership, derivative securities
3 terms
Form 3 regulatory
"an initial <b>Form 3</b> beneficial ownership report filed by Kevin Raidy"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
beneficial ownership financial
"an initial Form 3 <b>beneficial ownership</b> report filed by Kevin Raidy"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
derivative securities financial
"No <b>derivative securities</b> are reported. The derivativeSummary is empty"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
FAQ
What does the LTGO Form 3 filed by Kevin Raidy report?
The Form 3 for LTGO reports that director Kevin Raidy has no reportable equity holdings or transactions. It is an initial statement of beneficial ownership with all transaction and holding counts shown as zero.
Is Kevin Raidy a director or officer of Latigo Biotherapeutics, Inc. (LTGO)?
The filing identifies Kevin Raidy as a director of Latigo Biotherapeutics, Inc. He is not reported as an officer, ten percent owner, or in any other role on this Form 3.
Does the LTGO Form 3 show any insider buy or sell transactions?
No. The Form 3 for LTGO shows zero buy, sell, acquire, dispose, or other transactions. All transaction-related counts, including net buy/sell shares, are reported as 0.
Are there any derivative securities reported for LTGO on this Form 3?
No derivative securities are reported. The derivativeSummary is empty and the filing lists 0 derivative transactions and 0 exercise events, indicating no options or similar instruments disclosed here.
Does the LTGO Form 3 indicate use of a Rule 10b5-1 trading plan?
No. The Form 3 data show the Rule 10b5-1 plan indicator as null, and there are no footnote disclosures about trading plans. Since there are no transactions, trading-plan status is not a factor in this filing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
